E2F8-induced GRPEL2 promoted colorectal cancer progression via targeting TIGAR
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals GRPEL2 as an oncogene driving colorectal cancer (CRC) progression by disrupting mitochondrial function. Targeting the E2F8/GRPEL2/TIGAR pathway offers a promising therapeutic strategy for CRC.
Area Of Science
- Oncology
- Molecular Biology
- Mitochondrial Biology
Background
- Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide.
- GRPEL2 is implicated in mitochondrial regulation and cancer, but its role in CRC is unclear.
Purpose Of The Study
- To elucidate the function of GRPEL2 in CRC progression and mitochondrial regulation.
- To identify potential therapeutic targets within the GRPEL2 pathway.
Main Methods
- RNA-sequencing analysis of TCGA data and qPCR validation.
- In vitro and in vivo assays for cell proliferation, migration, and tumorigenesis.
- Mitochondrial function assessment using various staining and microscopy techniques.
- Protein-protein interaction studies (LC-MS/MS, Co-IP) and gene regulation assays (Luciferase, ChIP).
Main Results
- GRPEL2 is upregulated in CRC tissues and associated with poor prognosis.
- GRPEL2 inhibition impairs CRC cell proliferation and migration via mitochondrial injury.
- TIGAR interacts with GRPEL2 and can rescue CRC progression upon GRPEL2 inhibition.
- E2F8 acts as an upstream regulator, inducing GRPEL2 transcription in CRC.
Conclusions
- GRPEL2 plays an oncogenic role in CRC development.
- The E2F8/GRPEL2/TIGAR pathway is a key molecular mechanism in CRC.
- This pathway represents a novel therapeutic target for CRC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.